Sander, Christian
Schmidt, Jonathan M.
Mergl, Roland
Schmidt, Frank M.
Hegerl, Ulrich
Funding for this research was provided by:
junior research grant by the Medical Faculty, University of Leipzig
Article History
Received: 3 April 2018
Accepted: 21 September 2018
First Online: 10 October 2018
Competing Interests
: The authors have the following conflicts to declare: Within the last three years, Prof. Hegerl was an advisory board member for Lundbeck, Takeda Pharmaceuticals, Servier and Otsuka Pharma; a consultant for Bayer Pharma; and a speaker for Bristol-Myers Squibb, Medice Arzneimittel, Novartis and Roche Pharma. Dr. Mergl had a Consultancy Agreement with Nycomed, a Takeda company. The other authors have no financial or competing interests to declare.